Health Condition 1: H433- Other vitreous opacities
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Participants presenting with symptomatic vitreous floaters persisting for more than three months. They should have a clear ocular media to allow a clear view of the vitreous.
Exclusion criteria
Exclusion criteria: Presence of vitreous hemorrhage, asteroid hyalosis Opacification of lens, cornea or vitreous. Retinal diseases (e.g., Pathological myopia, retinal breaks or detachments, age-related macular degeneration, diabetic retinopathy, and branch retinal vein occlusion) Patients with Aspartate Amino Transferase (AST) and or Alanine Amino Transferase (ALT) levels greater than 2 times the upper normal limit, or Patients with S. Creatinine greater than the upper limits of the normal. History of malignancy within five years. History of hypersensitivity to the trial drug or any of its ingredients. Continuing addiction to smoking and usage of tobacco in any form Individuals simultaneously or previously (within 30 days before the investigation starts) participated in a clinical investigation using experimental drugs or devices.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The average change from baseline in the Floater Disturbance Questionnaire score compared to baseline at the end of 90 days.Timepoint: The average change from baseline in the Floater Disturbance Questionnaire score compared to baseline at the end of 90 days. | — |
Secondary
| Measure | Time frame |
|---|---|
| The average change from baseline in the NEI VFQ-25 score compared to baseline at the end of 90 days.Timepoint: 90 days;The average changes from baseline in the LFT and KFT, values compared to baseline at the end of 90 days. Timepoint: 90 days;Participant-reported adherence, defined as taking or not taking study medication. Timepoint: 90 days | — |
Countries
India
Contacts
National Ayurveda Research Institute fort Panchakrma , Cheruthuruthy